Details
| Translated title of the contribution | Topical diclofenac (Emulgel) vs. oral NSAIDs in therapy of gonarthrosis and fingerarthrosis - A cost analysis: a Cost Analysis |
|---|---|
| Original language | Multiple languages |
| Pages (from-to) | 61-68 |
| Number of pages | 8 |
| Journal | Aktuelle Rheumatologie |
| Volume | 25 |
| Issue number | 1-2 |
| Publication status | Published - Feb 2000 |
Abstract
Due to the high cost involved, it has often been discussed in the past to exclude topical NSAIDs for rheumatoid diseases from reimbursement. Therefore, we conducted a comparative cost analysis to get some information on the cost of therapy of one episode of osteoarthritis of knee and/or finger. 154 office-based physicians (GPs, specialists in internal medicine, orthopaedic surgeons, rheumatologists) documented the data of 1525 patients treated with either a topical or systemic NSAID due to an episode of osteoarthritis of the knee and/or finger. Three different therapeutic regimes were identified: (1) Therapy with a topical NSAID only (458 patients), (2) therapy with oral NSAIDs only (564 patients), (3) topical as well as systemic therapy with NSAID (503 patients). We analysed the treatment costs from the perspective of the payers (sickness funds). The mean costs per patient per episode of osteoarthritis of the finger and/or the knee were DM 497.16. The mean treatment costs differentiated according to the treatment groups were DM 216.47 per patient (1st group), DM 592.28 per patient (2nd group), DM 646.08 per patient (3rd group). High cost items in group 2 and 3 were inpatient costs due to osteoarthritis and due to side effects of the systemic therapy. The consequences of excluding topical NSAR from reimbusement is discussed from the perspective of social health insurance bodies.
ASJC Scopus subject areas
- Medicine(all)
- Rheumatology
Cite this
- Standard
- Harvard
- Apa
- Vancouver
- BibTeX
- RIS
In: Aktuelle Rheumatologie, Vol. 25, No. 1-2, 02.2000, p. 61-68.
Research output: Contribution to journal › Article › Research › peer review
}
TY - JOUR
T1 - Topisches Diclofenac versus orale NSAR in der Therapie der Gonarthrose und Fingerarthrose
T2 - Eine Kostenanalyse
AU - Schöffski, O.
AU - Ruof, J.
AU - Pirk, O.
AU - Graf Von Der Schulenburg, J. M.
AU - Zeidler, H.
PY - 2000/2
Y1 - 2000/2
N2 - Due to the high cost involved, it has often been discussed in the past to exclude topical NSAIDs for rheumatoid diseases from reimbursement. Therefore, we conducted a comparative cost analysis to get some information on the cost of therapy of one episode of osteoarthritis of knee and/or finger. 154 office-based physicians (GPs, specialists in internal medicine, orthopaedic surgeons, rheumatologists) documented the data of 1525 patients treated with either a topical or systemic NSAID due to an episode of osteoarthritis of the knee and/or finger. Three different therapeutic regimes were identified: (1) Therapy with a topical NSAID only (458 patients), (2) therapy with oral NSAIDs only (564 patients), (3) topical as well as systemic therapy with NSAID (503 patients). We analysed the treatment costs from the perspective of the payers (sickness funds). The mean costs per patient per episode of osteoarthritis of the finger and/or the knee were DM 497.16. The mean treatment costs differentiated according to the treatment groups were DM 216.47 per patient (1st group), DM 592.28 per patient (2nd group), DM 646.08 per patient (3rd group). High cost items in group 2 and 3 were inpatient costs due to osteoarthritis and due to side effects of the systemic therapy. The consequences of excluding topical NSAR from reimbusement is discussed from the perspective of social health insurance bodies.
AB - Due to the high cost involved, it has often been discussed in the past to exclude topical NSAIDs for rheumatoid diseases from reimbursement. Therefore, we conducted a comparative cost analysis to get some information on the cost of therapy of one episode of osteoarthritis of knee and/or finger. 154 office-based physicians (GPs, specialists in internal medicine, orthopaedic surgeons, rheumatologists) documented the data of 1525 patients treated with either a topical or systemic NSAID due to an episode of osteoarthritis of the knee and/or finger. Three different therapeutic regimes were identified: (1) Therapy with a topical NSAID only (458 patients), (2) therapy with oral NSAIDs only (564 patients), (3) topical as well as systemic therapy with NSAID (503 patients). We analysed the treatment costs from the perspective of the payers (sickness funds). The mean costs per patient per episode of osteoarthritis of the finger and/or the knee were DM 497.16. The mean treatment costs differentiated according to the treatment groups were DM 216.47 per patient (1st group), DM 592.28 per patient (2nd group), DM 646.08 per patient (3rd group). High cost items in group 2 and 3 were inpatient costs due to osteoarthritis and due to side effects of the systemic therapy. The consequences of excluding topical NSAR from reimbusement is discussed from the perspective of social health insurance bodies.
UR - http://www.scopus.com/inward/record.url?scp=0343618783&partnerID=8YFLogxK
U2 - 10.1055/s-2008-1043511
DO - 10.1055/s-2008-1043511
M3 - Article
AN - SCOPUS:0343618783
VL - 25
SP - 61
EP - 68
JO - Aktuelle Rheumatologie
JF - Aktuelle Rheumatologie
SN - 0341-051X
IS - 1-2
ER -